BIC Securities

Our company

BIC Securities is a leading independent corporate finance advisory firm acting mainly in Russia, Ukraine and the Baltics

Through our network and contacts we are well positioned to execute domestic and cross border equity transactions, primarily mergers & acquisitions (M&A), in our core markets as well as in other countries of Europe and CIS

Core markets:

Russian Federation

Ukraine

Baltic States – Latvia, Lithuania and Estonia

Scandinavian Countries

Other markets (also through partners' network):

UK, Germany, France

Czech Republic, Slovakia, Poland, Hungary, Slovenia, Romania, Bulgaria, Serbia

Other selected Eastern European and CIS countries

What's new



BIC Securities advised shareholders of Petroholod - #1 ice-cream producer in the North-West Federal District of Russia 28/05/2020 Petroholod is one of the oldest and largest ice-cream makers in Saint-Petersburg, Leningrad region and North-West Federal District of Russia... Read more
BIC Securities assisted Amber Beverage Group on acquiring a controlling interest in Mountain Spirits, a leading independent Austria alcohol distributor and wholesaler 11/12/2019 Amber Beverage Group (ABG), the largest alcohol manufacturer and distributor in the Baltics and part of SPI global group, acquired a controlling interest in Mountain Spirits, allowing ABG to establish a powerful footprint in Central Europe as well as the strategically important Alps... Read more
BIC Securities advised Creative Mobile, the largest mobile game developer and publisher in the Baltics, in its Series A financing round 10/04/2019 Creative Mobile, the Estonia-based mobile game developer and publisher, has raised its first capital round from a private investor, allowing the company to expand its game development capacity and streamline its user acquisition... Read more
BIC Securities advised Otravo in acquisition of Interneto Partneris, Lithuania-based Online Travel Company 18/10/2017 Otravo, one of the market leaders in the area of online travel in Northwest Europe is taking over Lithuania-based online travel company Interneto Partneris, allowing Otravo to expand its operations in the Baltic States... Read more
BIC Securities announces the successful completion of another M&A transaction in the Russian pharmaceutical sector, in which BIC Securities acted as an exclusive buy-side advisor to Takeda Pharmaceuticals on acquiring of IP rights for certain OTC and FS products from company Unipharm Inc. (USA) 01/09/2017 On September 01, 2017 Takeda Pharmaceuticals (Takeda) (TYO: 4502), a leading pharmaceutical company in Japan and one of the leading companies in Asia and worldwide, completed the acquisition of intellectual property rights for certain OTC and FS products from company Unipharm Inc. (USA), including worldwide rights for Vitrum vitamin brand... Read more
BIC Securities advised Amber Beverage Group on acquiring a stake in Cellar Trends, a leading independent UK alcohol distributor 15/05/2017 Amber Beverage Group (ABG), the largest alcohol manufacturer and distributor in the Baltics and part of SPI global group, acquired a significant minority stake in Cellar Trends, allowing the Company to significantly increase its position on the UK market... Read more
BIC Securities acted as exclusive financial adviser to Digitalas Ekonomikas Attistibas Centrs (DEAC), leading Baltic data center services provider in attracting investment from BPM Mezzanine Fund 05/10/2016 BPM Mezzanine Fund SICAV-SIF, SCA (BPM) has invested in the leading Baltic data center operator DEAC to support its growth... Read more
BIC Securities sponsored Russian Pharmaceutical Forum held by Adam Smith Conferences, which took place in Saint Petersburg on May 17-18, 2016 18/05/2016 Russian Pharmaceutical Forum is the foremost gathering of top management of international and local pharmaceutical producers, distributors and retailers... Read more
BIC Securities advised Russian pharmaceutical producer DIOD (MICEX:DIOD) on sale of Orvirem brand portfolio to Alvogen 01/01/2016 DIOD, Russian pharmaceutical producer has completed the transaction on sale of Orvirem product brand portfolio, including trademarks and other product related IP rights, to Alvogen, a leading international pharmaceutical company... Read more

Quick search